Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
HM Colhoun, I Lingvay, PM Brown, J Deanfield… - Nature Medicine, 2024 - nature.com
The SELECT trial previously reported a 20% reduction in major adverse cardiovascular
events with semaglutide (n= 8,803) versus placebo (n= 8,801) in patients with …
events with semaglutide (n= 8,803) versus placebo (n= 8,801) in patients with …
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with
type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo …
type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo …
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major
adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease …
adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease …
Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
V Perkovic, KR Tuttle, P Rossing… - … England Journal of …, 2024 - Mass Medical Soc
Background Patients with type 2 diabetes and chronic kidney disease are at high risk for
kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would …
kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would …
Semaglutide and cardiovascular outcomes in obesity without diabetes
AM Lincoff, K Brown-Frandsen… - … England Journal of …, 2023 - Mass Medical Soc
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
[HTML][HTML] Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide …
KR Tuttle, H Bosch-Traberg, DZI Cherney, S Hadjadj… - Kidney international, 2023 - Elsevier
Glucagon-like peptide-1 receptor agonists reduce albuminuria and may stabilize the
estimated glomerular filtration rate (eGFR) in people with type 2 diabetes (T2D). In this post …
estimated glomerular filtration rate (eGFR) in people with type 2 diabetes (T2D). In this post …
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6
EM Apperloo, DZI Cherney, AB Kuhlman… - Nephrology Dialysis …, 2024 - academic.oup.com
Background This post hoc analysis explored the effects of semaglutide on estimated
glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body …
glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body …
Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice
B Aviles Bueno, MJ Soler… - Clinical Kidney …, 2022 - academic.oup.com
Background Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown
nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety …
nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety …
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
J Deanfield, S Verma, BM Scirica, SE Kahn… - The Lancet, 2024 - thelancet.com
Background Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse
cardiovascular events (MACE) in people with overweight or obesity, but the effects of this …
cardiovascular events (MACE) in people with overweight or obesity, but the effects of this …